Marshall Wace LLP Decreases Stake in LivaNova PLC $LIVN

Marshall Wace LLP lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 26.5% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 814,696 shares of the company’s stock after selling 293,341 shares during the quarter. Marshall Wace LLP’s holdings in LivaNova were worth $36,678,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LIVN. Vanguard Group Inc. increased its position in shares of LivaNova by 13.5% during the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock valued at $104,755,000 after acquiring an additional 316,993 shares during the last quarter. Deutsche Bank AG boosted its position in LivaNova by 84.7% in the first quarter. Deutsche Bank AG now owns 90,333 shares of the company’s stock worth $3,548,000 after purchasing an additional 41,428 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in LivaNova by 890.9% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 105,059 shares of the company’s stock valued at $4,127,000 after purchasing an additional 94,457 shares during the period. Invesco Ltd. increased its position in shares of LivaNova by 13.4% during the 1st quarter. Invesco Ltd. now owns 126,266 shares of the company’s stock valued at $4,960,000 after purchasing an additional 14,892 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of LivaNova during the 1st quarter worth $30,954,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

LIVN has been the topic of a number of research analyst reports. Robert W. Baird boosted their price target on shares of LivaNova from $63.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a research note on Wednesday, September 3rd. Barclays increased their target price on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Wall Street Zen cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, The Goldman Sachs Group set a $55.00 price objective on LivaNova and gave the company a “neutral” rating in a research note on Wednesday, October 1st. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and an average target price of $62.43.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $63.36 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $3.46 billion, a PE ratio of -15.84 and a beta of 1.02. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $64.45. The company has a 50-day moving average price of $55.14 and a two-hundred day moving average price of $50.93.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.